Pfizer Inc. (NYSE:PFE) Shares Sold by Wilkins Investment Counsel Inc.

Wilkins Investment Counsel Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 258,686 shares of the biopharmaceutical company’s stock after selling 5,248 shares during the quarter. Wilkins Investment Counsel Inc.’s holdings in Pfizer were worth $6,863,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Fiduciary Group LLC increased its position in shares of Pfizer by 36.5% during the fourth quarter. Fiduciary Group LLC now owns 117,669 shares of the biopharmaceutical company’s stock worth $3,122,000 after acquiring an additional 31,479 shares during the period. Teacher Retirement System of Texas increased its position in shares of Pfizer by 93.3% during the fourth quarter. Teacher Retirement System of Texas now owns 1,969,261 shares of the biopharmaceutical company’s stock worth $52,244,000 after acquiring an additional 950,358 shares during the period. Royal London Asset Management Ltd. increased its position in shares of Pfizer by 2.8% during the fourth quarter. Royal London Asset Management Ltd. now owns 2,461,076 shares of the biopharmaceutical company’s stock worth $65,292,000 after acquiring an additional 67,788 shares during the period. Credit Capital Investments LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $260,000. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $2,077,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PFE shares. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

NYSE PFE opened at $26.18 on Thursday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market capitalization of $148.35 billion, a PE ratio of 18.57, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a fifty day moving average of $26.19 and a two-hundred day moving average of $27.08. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.